Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun;128(12):2295-2306.
doi: 10.1038/s41416-023-02240-y. Epub 2023 Apr 12.

Tumour budding-based grading as independent prognostic biomarker in HPV-positive and HPV-negative head and neck cancer

Fabian Stögbauer #  1 , Susanne Beck #  2 , Iordanis Ourailidis  2 , Jochen Hess  3   4 , Christopher Poremba  5 , Maren Lauterbach  6 , Barbara Wollenberg  6 , Anna Maria Stefanie Buchberger  6 , Moritz Jesinghaus  1   7 , Peter Schirmacher  2   8 , Albrecht Stenzinger  2   8 , Wilko Weichert  1   8 , Melanie Boxberg  9   10   11 , Jan Budczies  12   13
Affiliations

Tumour budding-based grading as independent prognostic biomarker in HPV-positive and HPV-negative head and neck cancer

Fabian Stögbauer et al. Br J Cancer. 2023 Jun.

Erratum in

Abstract

Background: The prognostic significance of tumour budding (TB) and minimal cell nest size (MCNS) was shown in human papillomavirus (HPV)-negative head and neck squamous cell carcinomas (HNSCC). However, the optimisation of cutpoints, the prognostic impact in HPV-positive HNSCC, and the comparison with other histopathological grading systems are insufficiently investigated.

Methods: TB and MCNS were analysed digitally in 1 and 10 high-power fields (HPF) of 331 HPV-positive and HPV-negative cases from TCGA. Optimising the cutpoints a new cellular dissociation grading (CDG) system was defined and compared to the WHO grading and the Brandwein-Gensler (BG) risk model.

Results: The two-tiered CDG system based solely on TB yielded optimal prognostic stratification with shortened overall survival for CDG-high cases. Optimal cut-offs were two buds (1 HPF) and six buds (10 HPF), respectively. Analysing MCNS did not add prognostic significance to quantifying TB. CDG was a significant prognostic marker in HPV-negative and HPV-positive tumours and prognostically superior to the WHO and BG systems. High CDG was associated with clinically occult lymph-node metastases.

Conclusions: The most comprehensive study of TB in HNSCC so far confirmed its prognostic impact in HPV-negative tumours and for the first time in HPV-positive tumours. Further studies are warranted to evaluate its applicability for therapy guidance in HNSCC.

PubMed Disclaimer

Conflict of interest statement

PS: Speaker’s fees: AstraZeneca, Incyte, Janssen. Advisory Boards: BMS, MSD, AstraZeneca, Roche. Funding for research: Roche, Chugai, BMS, Novartis. AS: Advisory Board/Speaker’s Bureau: Astra Zeneca, AGCT, Bayer, BMS, Eli Lilly, Illumina, Janssen, MSD, Novartis, Pfizer, Roche, Seattle Genetics, Takeda, Thermo Fisher. Grants: Bayer, BMS, Chugai, Incyte. WW: Advisory Boards and speaker’s fees: Roche, MSD, BMS, AstraZeneca, Pfizer, Merck, Lilly, Boehringer, Novartis, Takeda, Bayer, Amgen, Astellas, Eisai, Illumina, Siemens, Agilent, ADC, GSK and Molecular Health. Funding for research: Roche, MSD, BMS and AstraZeneca. MB: Funding through Deutsche Krebshilfe (German Cancer Aid). Advisory Board and speaker´s fee: BMS, MSD. Funding: BMS. JB: Funding through Deutsche Krebshilfe (German Cancer Aid). The remaining authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Evaluation of tumour budding (TB) in H&E-stained tissue sections of HNSCC.
While tumour budding (TB) was absent in the TCGA cases a and b, strong TB was observed in the TCGA cases c and d. Exemplary budding foci are highlighted by arrows.
Fig. 2
Fig. 2. Optimisation of the cellular dissociation grading (CDG) system.
Two four-tiered grading systems were investigated, both based on tumour classification as CDG1, CDG2 and CDG3 and an additional split of the CDG2 class. a, b The set of CDG2 tumours was split based on the number of budding foci. Hazard ratios compared to CDG1 tumours increased and reached 1.5, 2.1, and 2.5 for CDG2/weak TB, CDG2/moderate TB and CDG3 tumours. c, d The set of CDG2 tumours was split based on the presence or absence of single-cell invasion (SCI). Counterintuitively, CDG2 tumours without SCI showed a (non-significant) trend to unfavourable prognosis compared to CDG2 tumours with SCI. e Relation between the number of budding foci, the classification of TB, and the CDG systems.
Fig. 3
Fig. 3. Association of overall survival (OS) with cellular dissociation grading (CDG).
Performance of the 3-tiered CDG system and of the 2-tiered CDG system in the study cohort (a, b), in the subcohort of HPV-negative tumours (c, d) and in the subcohort of HPV-positive tumours (e, f).
Fig. 4
Fig. 4. Subgroup analysis of the prognosticity of cellular dissociation grading (CDG).
Comparison of CDG high with CGD low tumours with respect to PFI (a) and OS (b). N, number of patients, E, number of events, HR, hazard ratio, CI, 95% confidence interval.
Fig. 5
Fig. 5. Comparison of the 1-HPF and the 10-HPF method for the evaluation of TB.
Evaluation of TB in 10 high-power fields (HPF) and in a single HPF. Linear regression revealed that the detected number of budding foci differed by a factor of about three.
Fig. 6
Fig. 6. Analysis of clinically nodal-negative (cN0) patients.
A Higher numbers of budding foci in pathologically nodal-positive (pN+) compared to pN0 patients. B Increasing percentages of pN+ patients with increasing TB.
See this image and copyright information in PMC

Comment in

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Leemans CR, Snijders PJF, Brakenhoff RH. The molecular landscape of head and neck cancer. Nat Rev Cancer. 2018;18:269–82. doi: 10.1038/nrc.2018.11. - DOI - PubMed
    1. LeConte BA, Szaniszlo P, Fennewald SM, Lou DI, Qiu S, Chen NW, et al. Differences in the viral genome between HPV-positive cervical and oropharyngeal cancer. PLoS ONE. 2018;13:e0203403. doi: 10.1371/journal.pone.0203403. - DOI - PMC - PubMed
    1. Taberna M, Mena M, Pavón MA, Alemany L, Gillison ML, Mesía R. Human papillomavirus-related oropharyngeal cancer. Ann Oncol. 2017;28:2386–98. doi: 10.1093/annonc/mdx304. - DOI - PubMed

Publication types